Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Eudocia C. Quant"'
Publikováno v:
Current Cancer Therapy Reviews. 7:65-77
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e046471b75899c35379abc1b0e9a840
https://doi.org/10.2174/157339411794474146
https://doi.org/10.2174/157339411794474146
Autor:
Patrick Y. Wen, Eudocia C. Quant
Publikováno v:
Neuroimaging Clinics of North America. 20:425-448
The prognosis for glioblastoma is poor despite optimal therapy with surgery, radiation, and chemotherapy. New therapies that improve survival and quality of life are needed. Research has increased our understanding of the molecular pathways important
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33f8d22f8a57ccf386aef687e133331e
https://doi.org/10.1016/j.nic.2010.04.007
https://doi.org/10.1016/j.nic.2010.04.007
Publikováno v:
Current Treatment Options in Neurology. 12:321-333
Opinions vary on the best treatment options for recurrent high-grade glioma. Some argue that bevacizumab should become standard of care for patients with recurrent glioblastoma, especially in light of recent FDA approval for this indication. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::037ccb34ff677f84272553c7cf186c17
https://doi.org/10.1007/s11940-010-0078-5
https://doi.org/10.1007/s11940-010-0078-5
Autor:
Patrick Y. Wen, Brian J. Scott, Tracy T. Batchelor, Margaret B. McNamara, Peter A. Ryg, Eudocia C. Quant
Publikováno v:
Neuro-Oncology. 12:603-607
Agents targeting the vascular endothelial growth factor (VEGF) pathway are being used with increasing frequency in patients with recurrent high-grade glioma. The effect of more than one antiangiogenic therapy given in succession has not been establis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::877a119b8cf41c11a498cf5dad3d4834
https://doi.org/10.1093/neuonc/nop073
https://doi.org/10.1093/neuonc/nop073
Autor:
Patrick Y. Wen, Andrew D. Norden, A. S. Ciampa, Rameen Beroukhim, Debra LaFrankie, Sandra Ruland, Shota Tanaka, Eudocia C. Quant, Jan Drappatz, Lisa Doherty, Julia Bartolomeo
Publikováno v:
Journal of neuro-oncology. 106(1)
Venous thromboembolic events (VTE) are common in glioma patients and are typically treated with anticoagulant medications. The anti-angiogenic agent bevacizumab (BVZ) increases the risks of both VTE and hemorrhagic complications. Little is known abou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de30a06a28ec18c11fa869d9a5d94dde
https://pubmed.ncbi.nlm.nih.gov/21706358
https://pubmed.ncbi.nlm.nih.gov/21706358
Autor:
Nan Lin, Elizabeth B. Claus, Paul J. Kelly, Stephanie E. Weiss, Brian M. Alexander, Eudocia C. Quant
Publikováno v:
Cancer. 118(8)
BACKGROUND: Salvage stereotactic radiosurgery (SRS) is often considered in breast cancer patients previously treated for brain metastases. The goal of this study was to analyze clinical outcomes and prognostic factors for survival in the salvage sett
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a417e7523858f46afe160083d38b89c7
https://pubmed.ncbi.nlm.nih.gov/21918959
https://pubmed.ncbi.nlm.nih.gov/21918959
Publikováno v:
Lymphoma and Leukemia of the Nervous System ISBN: 9781441976673
The treatment of hematologic malignancies has markedly improved in recent decades. Patients are living longer, thus increasing the likelihood of long-term neurologic complications from chemotherapy. These neurologic sequelae are an important source o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b5ec018283fa951a7b81a0c4f2e8414
https://doi.org/10.1007/978-1-4419-7668-0_22
https://doi.org/10.1007/978-1-4419-7668-0_22
Autor:
Eudocia C. Quant, Patrick Y. Wen
Publikováno v:
Current oncology reports. 13(1)
Accuracy and reproducibility in determining response to therapy and tumor progression can be difficult to achieve for nervous system tumors. Current response criteria vary depending on the pathology and have several limitations. Until recently, the m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b637e2859b7d67a4aeebe3379c58c93b
https://pubmed.ncbi.nlm.nih.gov/21086192
https://pubmed.ncbi.nlm.nih.gov/21086192
Publikováno v:
Journal of neuro-oncology. 99(3)
Meningiomas are the most common primary brain tumor in adults. Although the majority of these tumors can be effectively treated with surgery and radiation therapy, an important subset of patients have inoperable tumors, or develop recurrent disease a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23822c964a8bf49b2ba0014d5ab5aaed
https://pubmed.ncbi.nlm.nih.gov/20820875
https://pubmed.ncbi.nlm.nih.gov/20820875
Autor:
Andrew D. Norden, Patrick Y. Wen, A. S. Ciampa, Debra LaFrankie, Christine Lu-Emerson, Rameen Beroukhim, Jan Drappatz, Lisa Doherty, Eudocia C. Quant, Sandra Ruland
Publikováno v:
Journal of neuro-oncology. 104(1)
There is no effective treatment for recurrent glioblastoma (GBM) after bevacizumab failure. Putative mechanisms of resistance to bevacizumab include increased pericyte coverage, mediated partly by platelet-derived growth factor receptor (PDGFR) signa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7aa4ba3577c5bce7a8d6f65a2e602e54
https://pubmed.ncbi.nlm.nih.gov/21153679
https://pubmed.ncbi.nlm.nih.gov/21153679